-- Days : -- HRS : -- MIN : -- SEC
Register for Free →

Multiple Sclerosis

Latest Content


Latest Videos


More News

Online systems, including telehealth, are imperative to maintaining optimal care for patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic, said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers, in an interview with The American Journal of Managed Care® (AJMC®).

The FDA approved Bristol Myers Squibb’s ozanimod (Zeposia) 0.92 mg as an oral treatment for relapsing forms of multiple sclerosis (RMS). Ozanimod can be used to treat clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Researchers developed a multisensor tool that quickly and simply records motor changes in patients with multiple sclerosis (MS), according to a study recently published in Annals of Clinical and Translational Neurology. Researchers hope the introduction of the device will lead to future developments in neurological vital signs using wearable technology.

Researchers determined that patients with multiple sclerosis (MS) present with significant Aqueduct of Sylvius enlargement over time, which may be attributable to regional atrophy changes and ex vacuo expansion of the aqueduct, according to a study recently published in Fluids and Barriers of the CNS.